Cargando…
FFPE breast tumour blocks provide reliable sources of both germline and malignant DNA for investigation of genetic determinants of individual tumour responses to treatment
BACKGROUND: Bio-banked formalin-fixed paraffin-embedded (FFPE) tissues provide an excellent opportunity for translational genomic research. Historically matched blood has not always been collected as a source of germline DNA. This project aimed to establish if normal FFPE breast tissue could be used...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6022520/ https://www.ncbi.nlm.nih.gov/pubmed/29700676 http://dx.doi.org/10.1007/s10549-018-4798-7 |
_version_ | 1783335695674245120 |
---|---|
author | Wilkins, Anna Chauhan, Ritika Rust, Alistair Pearson, Alex Daley, Frances Manodoro, Floriana Fenwick, Kerry Bliss, Judith Yarnold, John Somaiah, Navita |
author_facet | Wilkins, Anna Chauhan, Ritika Rust, Alistair Pearson, Alex Daley, Frances Manodoro, Floriana Fenwick, Kerry Bliss, Judith Yarnold, John Somaiah, Navita |
author_sort | Wilkins, Anna |
collection | PubMed |
description | BACKGROUND: Bio-banked formalin-fixed paraffin-embedded (FFPE) tissues provide an excellent opportunity for translational genomic research. Historically matched blood has not always been collected as a source of germline DNA. This project aimed to establish if normal FFPE breast tissue could be used as an alternative to blood. METHODS: Exome sequencing was carried out on matched tumour tissue, normal breast tissue and blood on five patients in the START trial. Retrieved samples had been archived at different centres for at least 13 years. Following tissue macro-dissection and DNA extraction, targeted exome capture was performed using SureSelect Human All Exome v5 reagents (Agilent). Illumina paired-end libraries were prepared from the captured target regions and sequenced on a HiSeq2500 (Illumina) acquiring 2 × 75 bp reads. Somatic variants were called using the MuTect software analysis tool and copy number abnormalities (CNA) were identified using CNVkit. Targeted sequencing and droplet digital PCR were used to validate somatic variants and CNA, respectively. RESULTS: Overlap of somatic variants and CNA called on tumour versus blood and tumour versus normal breast tissue was good. Agreement in somatic variant calling ranged from 76.9 to 93.6%. Variants with an allele frequency lower than 10% were more difficult to validate irrespective of the type of germline DNA used. Pearson’s correlation coefficients for paired comparisons of CNA using blood or normal tissue as reference ranged from 0.70 to 0.94. CONCLUSIONS: There is good correlation between the somatic mutations and CNA called using archived blood or normal breast tissue as germline reference material. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s10549-018-4798-7) contains supplementary material, which is available to authorised users. |
format | Online Article Text |
id | pubmed-6022520 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-60225202018-07-06 FFPE breast tumour blocks provide reliable sources of both germline and malignant DNA for investigation of genetic determinants of individual tumour responses to treatment Wilkins, Anna Chauhan, Ritika Rust, Alistair Pearson, Alex Daley, Frances Manodoro, Floriana Fenwick, Kerry Bliss, Judith Yarnold, John Somaiah, Navita Breast Cancer Res Treat Clinical Trial BACKGROUND: Bio-banked formalin-fixed paraffin-embedded (FFPE) tissues provide an excellent opportunity for translational genomic research. Historically matched blood has not always been collected as a source of germline DNA. This project aimed to establish if normal FFPE breast tissue could be used as an alternative to blood. METHODS: Exome sequencing was carried out on matched tumour tissue, normal breast tissue and blood on five patients in the START trial. Retrieved samples had been archived at different centres for at least 13 years. Following tissue macro-dissection and DNA extraction, targeted exome capture was performed using SureSelect Human All Exome v5 reagents (Agilent). Illumina paired-end libraries were prepared from the captured target regions and sequenced on a HiSeq2500 (Illumina) acquiring 2 × 75 bp reads. Somatic variants were called using the MuTect software analysis tool and copy number abnormalities (CNA) were identified using CNVkit. Targeted sequencing and droplet digital PCR were used to validate somatic variants and CNA, respectively. RESULTS: Overlap of somatic variants and CNA called on tumour versus blood and tumour versus normal breast tissue was good. Agreement in somatic variant calling ranged from 76.9 to 93.6%. Variants with an allele frequency lower than 10% were more difficult to validate irrespective of the type of germline DNA used. Pearson’s correlation coefficients for paired comparisons of CNA using blood or normal tissue as reference ranged from 0.70 to 0.94. CONCLUSIONS: There is good correlation between the somatic mutations and CNA called using archived blood or normal breast tissue as germline reference material. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s10549-018-4798-7) contains supplementary material, which is available to authorised users. Springer US 2018-04-26 2018 /pmc/articles/PMC6022520/ /pubmed/29700676 http://dx.doi.org/10.1007/s10549-018-4798-7 Text en © The Author(s) 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Clinical Trial Wilkins, Anna Chauhan, Ritika Rust, Alistair Pearson, Alex Daley, Frances Manodoro, Floriana Fenwick, Kerry Bliss, Judith Yarnold, John Somaiah, Navita FFPE breast tumour blocks provide reliable sources of both germline and malignant DNA for investigation of genetic determinants of individual tumour responses to treatment |
title | FFPE breast tumour blocks provide reliable sources of both germline and malignant DNA for investigation of genetic determinants of individual tumour responses to treatment |
title_full | FFPE breast tumour blocks provide reliable sources of both germline and malignant DNA for investigation of genetic determinants of individual tumour responses to treatment |
title_fullStr | FFPE breast tumour blocks provide reliable sources of both germline and malignant DNA for investigation of genetic determinants of individual tumour responses to treatment |
title_full_unstemmed | FFPE breast tumour blocks provide reliable sources of both germline and malignant DNA for investigation of genetic determinants of individual tumour responses to treatment |
title_short | FFPE breast tumour blocks provide reliable sources of both germline and malignant DNA for investigation of genetic determinants of individual tumour responses to treatment |
title_sort | ffpe breast tumour blocks provide reliable sources of both germline and malignant dna for investigation of genetic determinants of individual tumour responses to treatment |
topic | Clinical Trial |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6022520/ https://www.ncbi.nlm.nih.gov/pubmed/29700676 http://dx.doi.org/10.1007/s10549-018-4798-7 |
work_keys_str_mv | AT wilkinsanna ffpebreasttumourblocksprovidereliablesourcesofbothgermlineandmalignantdnaforinvestigationofgeneticdeterminantsofindividualtumourresponsestotreatment AT chauhanritika ffpebreasttumourblocksprovidereliablesourcesofbothgermlineandmalignantdnaforinvestigationofgeneticdeterminantsofindividualtumourresponsestotreatment AT rustalistair ffpebreasttumourblocksprovidereliablesourcesofbothgermlineandmalignantdnaforinvestigationofgeneticdeterminantsofindividualtumourresponsestotreatment AT pearsonalex ffpebreasttumourblocksprovidereliablesourcesofbothgermlineandmalignantdnaforinvestigationofgeneticdeterminantsofindividualtumourresponsestotreatment AT daleyfrances ffpebreasttumourblocksprovidereliablesourcesofbothgermlineandmalignantdnaforinvestigationofgeneticdeterminantsofindividualtumourresponsestotreatment AT manodorofloriana ffpebreasttumourblocksprovidereliablesourcesofbothgermlineandmalignantdnaforinvestigationofgeneticdeterminantsofindividualtumourresponsestotreatment AT fenwickkerry ffpebreasttumourblocksprovidereliablesourcesofbothgermlineandmalignantdnaforinvestigationofgeneticdeterminantsofindividualtumourresponsestotreatment AT blissjudith ffpebreasttumourblocksprovidereliablesourcesofbothgermlineandmalignantdnaforinvestigationofgeneticdeterminantsofindividualtumourresponsestotreatment AT yarnoldjohn ffpebreasttumourblocksprovidereliablesourcesofbothgermlineandmalignantdnaforinvestigationofgeneticdeterminantsofindividualtumourresponsestotreatment AT somaiahnavita ffpebreasttumourblocksprovidereliablesourcesofbothgermlineandmalignantdnaforinvestigationofgeneticdeterminantsofindividualtumourresponsestotreatment |